Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.57 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985879 | 0.81 | PNMT (0.54) | PNMTCYP2A6DPP4SMN1; SMN2CA12 | |
| SCHEMBL10154039 | 0.80 | PNMT (0.64) | PNMTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL9364845 | 0.80 | PNMT (0.64) | PNMTLMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL3981466 | 0.78 | CYP2A6 (0.47) | PNMTCYP2A6MEN1KMT2ACASP6 | |
| SCHEMBL3981462 | 0.77 | HTR2C (0.60) | LMNACYP2A6MEN1KMT2AALDH1A1 | |
| SCHEMBL1076217 | 0.73 | PNMT (1.00) | PNMTHTR2CHTR2B | |
| SCHEMBL20068178 | 0.73 | CYP2A6 (0.48) | LMNAL3MBTL1CYP2A6KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5682410 | 0.72 | PNMT (0.97) | PNMTHTR2CHTR2B | |
| SCHEMBL10154007 | 0.72 | PKM (0.67) | L3MBTL1ALDH1A1PKM | |
| SCHEMBL16566144 | 0.72 | PNMT (0.48) | PNMTTAS2R14LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1807409-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | Pharmacopeia Drug Discovery, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006044293-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | PNMT 150/4885TAS2R14 417/4885LMNA 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.